Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Cancer Lett. 2018 Nov 3;442:262–270. doi: 10.1016/j.canlet.2018.10.033

FIGURE 4: High-throughput drug screen identifies classes with and without efficacy against osteosarcoma.

FIGURE 4:

(A) Schematic overview of the high-throughput in-vitro screening assay using early phase cultures of xenograft cells and cell lines. (B) 21 test compounds that yielded the greatest and least cytotoxic effects in the single agent drug screen, and 7 standard-of-care agents (color scale: EC50 values, circle size: magnitude of activity from 0 – >3 log10 units). (C) Single agent drug screen of 373 compounds in 432 formulations sorted by mechanism of action, with dark blue showing low EC50 and light blue showing high EC50 values for compounds that fit a dose-response curve and had at least 1 data point above 1 log10 unit. .